Ovid Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OVID research report →
Range $5 – $8
Price Chart
About the company
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy.
- CEO
- Margaret Alexander
- IPO
- 2017
- Employees
- 23
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on OVID
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $415.21M
- P/E
- -12.50
- PEG
- -0.14
- P/S
- 286.15
- P/B
- 2.25
- EV/EBITDA
- -9.41
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -4700.28%
- Net Margin
- -2971.33%
- ROE
- -23.38%
- ROIC
- -32.19%
Latest fiscal year · YoY change
- Revenue
- $7.25M+1181.3%
- Gross Profit
- $6.95M+1128.3%
- Op Income
- $-42,439,000
- Net Income
- $-17,414,000+34.1%
- EPS
- $-0.23+37.8%
- OCF Growth
- +31.5%
- FCF Growth
- +31.6%
- 52W High
- $3.11
- 52W Low
- $1.26
- 50D MA
- $2.46
- 200D MA
- $2.43
- Beta
- 0.24
- RSI (14)
- 41
- Avg Volume
- 1.98M
No earnings-call transcripts are available for OVID yet.
- Free Float
- 88.7%
- Shares Outstanding
- 188.73M
- Float Shares
- 167.32M
of shares held by institutions
135 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 20.74M | ▲ 20.74M |
| Jupiter Topco LLC | 20.74M | ▲ 20.74M |
| Blackrock, Inc. | 12.05M | ▲ 1.23M |
| Eventide Asset Management, LLC | 11.81M | 0 |
| Affinity Asset Advisors, LLC | 10.14M | 0 |
| Vanguard Capital Management LLC | 7.83M | ▲ 68.25K |
| Balyasny Asset Management L.P. | 7.12M | ▲ 399.20K |
| Braidwell LP | 6.58M | ▲ 662.96K |
| State Street Corp | 6.20M | ▼ 1.70M |
| Adage Capital Partners Gp, L.L.C. | 6.16M | 0 |
| Federated Hermes, Inc. | 5.95M | 0 |
| Silverarc Capital Management, LLC | 5.95M | ▲ 2.85M |
Held by 136 ETFs
Biggest fund positions in OVID by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 6, 26 | Carter Charles Ross | other | 50,000 |
| Jul 6, 26 | Carter Charles Ross | other | 0 |
| Jul 6, 26 | Carter Charles Ross | other | 0 |
| Jul 6, 26 | Carter Charles Ross | other | 0 |
| Jun 15, 26 | Greka Anna | other | 130,000 |
| Jun 15, 26 | Greka Anna | other | 0 |
| Apr 7, 26 | PAPADOPOULOS STELIOS | other | 17,578 |
| Apr 7, 26 | Friedman Bart | other | 8,789 |
| Apr 7, 26 | Fitzgerald Kevin Joseph | other | 17,578 |
| Mar 23, 26 | LEVIN JEREMY M | other | 47,333 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OVID coverage
Recent articles, reports, and earnings notes.
No research on OVID yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OVID report →Ovid Therapeutics Sets Up 2027 Data Tests for Epilepsy and Brain Drug Programs
defenseworld.net · Nov 17
Ovid Therapeutics Inc. (OVID) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
seekingalpha.com · Nov 16
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
globenewswire.com · Nov 10
Critical Comparison: Ovid Therapeutics (NASDAQ:OVID) & Ono Pharmaceutical (OTCMKTS:OPHLF)
defenseworld.net · Nov 6
Ovid Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 5
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
prnewswire.com · Oct 15
Ovid Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 3
BlackRock Inc. Takes Position in Ovid Therapeutics $OVID
defenseworld.net · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.